Gadobutrol (Gadovist, BAY86-4875) + Gadopentetate Dimeglumine (Magnevist, BAY86-4882)

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
74
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Magnetic Resonance Imaging

Conditions

Magnetic Resonance Imaging

Trial Timeline

Jan 1, 2010 โ†’ Apr 1, 2011

About Gadobutrol (Gadovist, BAY86-4875) + Gadopentetate Dimeglumine (Magnevist, BAY86-4882)

Gadobutrol (Gadovist, BAY86-4875) + Gadopentetate Dimeglumine (Magnevist, BAY86-4882) is a phase 3 stage product being developed by Bayer for Magnetic Resonance Imaging. The current trial status is completed. This product is registered under clinical trial identifier NCT01050829. Target conditions include Magnetic Resonance Imaging.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01050829Phase 3Completed